Impax Laboratories Inc. (NASDAQ:IPXL): According to Piper Jaffray, Actavis’ recently approved generic form of Adderall XR will pressure volumes for Impax’s authorized generic, but the firm predicts that Shire’s brand name version will be more heavily impacted. Also, the firm notes that the royalty obligation Impax has on Shire could be reduced significantly as a result of an additional generic. Piper Jaffray views this weakness in Impax as a buying opportunity. The firm maintains an Overweight rating and a $32 price target on shares.
Merck & Co. Inc.’s (NYSE:MRK) PH III osteoporosis drug odanacatib is being overlooked by investors, claims Credit Suisse. The firm increased its its estimated for 2020 from $350M to $1.1B, and predicts increased focus on the drug due to 2 interim efficacy reports expected later this year. Shares are given an Outperform rating with a $45 price target, increased from $44.
Photronics Inc. (NASDAQ:PLAB): According to DA Davidson, a buying opportunity is created by the recent sell-off in Photronics. Due to its remping high-end IC foundry business, an emerging DRAM recovery, and continued AMOLED ramp, the firm believes that the company is in a great position for future growth. The shares are given a Buy rating with a $12 price target.
Comcast Corporation (NASDAQ:CMCSA) is still viewed as a relative outperformer by Brean Murray, but the firm trims its estimates as a result of various networks’ challenges including Cable Networks, NBC Broadcasting Network, and Filmed Entertainment. Based on an outlook for outperformance of core cable operations, the firm reiterates its Buy rating with a $35 price target.
Shire plc (NASDAQ:SHPGY): Cowen believes Shire’s weakness resulting from the approval of Actavis’ generic form of Adderall XR creates a buying opportunity. The firm predicts that any impact will be brief and manageable. Shares are given an Outperform rating.
Don’t Miss: MONSTER: Here’s Why Apple is the NEW Wal-Mart.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.